Covid-19 Vaccine Development:
There is a worldwide wait for the Corona vaccine. About 150 companies from all over the world are engaged in making a vaccine to eliminate the effect of Corona. Many have also claimed successful trials from its first phase to the third phase. Meanwhile, COVID vaccine is being claimed to come in the market at different times. If someone claims that the vaccine will come this year, then someone is claiming to have the vaccine by March 2021. But in the meantime, a new report is going to raise concerns of common people.
According to experts working in the field of vaccine development, before the end of 2021 an effective vaccine is very unlikely to be available to the general public. At the end of June 2020, researchers at Canada’s McGill University conducted a survey of 28 experts working in vaccinology. Most of the people polled were from Canadian or American academics. He had an average of 25 years of experience in his field.
Jonathan Kimmelman, a professor at McGill University, said in his statement that experts in our survey have forecasted vaccine development. These experts were generally less optimistic than anticipated by US public officials.
The vaccine will come by the end of 2021
On the paper published in the Journal of General Internal Medicine, senior author Kimelman said that the experts, in general, believe that the coronavirus vaccine may be available to the public by next summer if the best conditions are discussed. . But it is very unlikely. However, it is more likely that the vaccine will be available to the common people by the end of 2021. Maybe it will come on the market in 2022.
Fear of false start
Many experts also believe that some false start can occur before an effective vaccine is available. Patrick Kane, a postdoctoral fellow at McGill University, said that according to the survey we have conducted, he believes that 1 in 3 chances are that the vaccine will receive a safety warning label upon approval. There is a possibility of 4 out of 10 that there will be no report of efficiency in the study of the large area first.
2 failures can be seen
The study also showed that one-third of the people surveyed believe that there is a possibility of facing two major failures in vaccine development. The researchers said that the first is that after the vaccine is widely marketed, there will be a warning from the US FDA regarding its negative effects. Apart from this, there were reports of null or negative results in the first large area trial in the US or Canada. a
Work is happening fast
Stephen Brummel, an associate professor at Carnegie Mellon University in the US, said that our study found that experts are broadly in agreement about the SARS-CoV-2 vaccine deadline. He said in a statement that although this survey does not monitor very optimistic government estimates, it shows the perception that researchers are on a fast pace of development.